A South Korea–based team engineered a new bispecific TCR-like antibody targeting the PRAME complex, reporting laboratory validation that could expand cancer immunotherapy to patients previously excluded from the field’s most successful targets. The work, published in Cancer Immunology, Immunotherapy, focuses on a cancer-associated antigen strategy designed to recruit immune attack more effectively. The PRAME complex approach reflects a continued push toward next-generation targets that aim to broaden response beyond current biomarker-defined populations. The report emphasizes preclinical development and validation of the binding and functional rationale. For biotech teams, it underscores how TCR-like bispecific formats remain a key lever in improving tumor recognition while attempting to manage selectivity and efficacy.